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ABSTRACT
“The health of the people is really the foundation on which all their happiness and all their powers as a state depend.” - Benjamin Disraeli.
A healthy society is obviously a healthy nation. Being healthy is a result of various factors such as lifestyle, income, choices, society, access to medical 
facilities, culture, and family. The life expectancy (LE) (i.e., average years a person is anticipated to live has almost doubled) in the past century and 
medical breakthroughs had a profoundly positive impact on human LE. The average LE of the people in India was 49.7 years during 1970-1975 
gradually increased to the level of 68.45 years in 2016 according to the world LE reports. The objective here is to understand the factors determining 
LE and whether there are any possibilities for considerable improvements in LE in India due to various economic policies by the government. Statistical 
reports from various organizations are analyzed, and the conclusion is that the government spending on health care and awareness is to be enhanced.
Keywords: Life expectancy, Health care, Mortality, Birth rate, Death rate, etc.
INTRODUCTION
India is a land of villages. According to the reports from the Government 
of India, 2011, the Annual Exponential Growth Rate of India’s population 
is 1.21 billion of which 623.72 million are males (51.54%) and 586.46 
million females (48.46%), as compared to the population of 381 million 
in 1951. The majority of the people live in villages and the rural and 
urban population constitute 68.9% (83.3 crore) and 31.1% (31.1 crore) 
respectively of the whole population of the country [1].
There is a major improvement in the life expectancy (LE) of the people 
in India over the last century. Bhat (1987) has identified the reasons like 
reduction in the death rates (DRs) of children, mothers, and infants [2]. 
Saikia and Thomas (2011), in their study, have pointed out that LE in India 
has drastically changed due to declining DRs among elders and adults [3].
WHAT CAUSES DEATH?
In India, there are many reasons for death to occur, but some of the 
common reasons are 38% of the death is due to a communicable 
disease such as malaria, tuberculosis, maternal, prenatal, and 
nutritional disorders. 10% of the death is due to injuries and 52% of 
the death is due to noncommunicable diseases (NCDs) such as diabetes, 
mental illness, hypertension, and cancer which is more common among 
the elderly group. Due to environmental and socioeconomic factors, 
developing countries like India are very much prone to virus related 
diseases such as Zika, HINI, and SARS [4] Fig. 1.
HOW MUCH DO COUNTRIES SPEND ON HEALTH CARE?
The total health-care spending varies across countries and US ranks high 
as 17% of the gross domestic product (GDP) is spent on the health care, 
whereas the level of spending as a percent of GDP has increased from 
3.8% to 4.3% in India, in 2012. The basic health needs are met at least 
when a country spends at least 5-6% of its GDP on health care [5] Table 1.
It is evident that a country needs to contribute more on social health 
care and 73% of the current health expenditure (CHE) is contributed 
by the households. Individuals pay from out of pocket (OOP) and that 
accounts to 69% by households. High OOP spending is due to the lack of 
government spending on health, constituting just 1.15% of GDP which 
accounts to 30% of CHE - lowest among the BRICS nations.
In 2013-2014, the total health-care expenditure (THE) of India was Rs. 
4.5 lakh crores, a third of all money Rs. 1.5 lakh crores (35.7%) was 
spent in pharmacies. Rs. 88.5 thousand crores 21% was spent in private 
hospitals, almost double compared to that of government hospitals 
which consume 41.7 thousand crores (9.9%). Around Rs. 28 thousand 
crores (6.7%) was spent in labs and medical diagnostics. The 
estimated total government health expenditure in FY 2013-2014 is 
Rs. 129,778 crores. This equates to 1.15% of GDP, 3.8% of General 
Government Expenditure, 28.6% of THE, and Rs. 1042/capita. The 
Union Government share of the total government health expenditure 
(including health insurance schemes through Union government) 
is Rs. 44,564 crores, which equates to 0.4% of GDP, 34% of the total 
government health expenditure and Rs. 358/capita. The share of 
the total government health expenditure of States/UT’s and local 
Governments (combined) and health insurance schemes through state 
government is estimated at Rs. 85,215 crores, which equates 0.75% of 
GDP, 66% of total government health expenditure and Rs. 684/capita.
HOW HEALTHY IS INDIA?
The health statistics have shown considerable progress over time and by 
2013 there was a gradual decrease in birth rate, death rate, total fertility 
rate, maternal mortality ratio and infant mortality ratio when compared 
to the vital statistics of 1951. The Life expectancy of male in 1951 was 
36.1 years has considerably improved to 65.8 by 2013 (Table 2). The 
“Technical Group on Population Projections” has anticipated that by 
2020 LE of male is expected to arrive at 68.8 years and 69.8 years by 
2025 from the existing level. The LE of female population is expected to 
reach 7 1.1 years by 2020 and 72.3 years by 2025.
THE INDIAN PHARMACEUTICAL COMPANIES
India is the fastest and the fifth biggest economy in the world according 
to the reports of Euromonitor. The Indian Pharmaceutical Industry 
occupies a significant position globally, and Indian companies enjoy 
a strong presence in the US generics market, commanding a share 
of 19% in 2014 as against 13% in 2010. It is ranked eighth by value 
(USD 29 bn) and continues to intensify high growth rate, between 15 
and 20%, strongly in competition with China [6]. As on 31st March 
2015, there are 153,655 sub centers, 5396 community health centers, 
and 25,308 primary health centers implemented in the country to 
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cater to the needs of the people [7]. The Government of India plays 
a steadfast role in implementing the “Health for All” program. The 
Indian Pharmaceutical Market (IPM) has developed enormously and 
is now anticipated that the IPM will touch around USD 55 billion by 
2020. The top ten pharma companies from India have captivated the 
global markets (Table 3). Statistics show that investments in research 
and development of the top 25 Indian companies have grown from INR 
5060 crores (USD 1012 million) in FY 2012-2013 to INR 6103 crores 
(USD 1110 million) in FY 2013-2014 [7]. India is the fourth leading 
manufacturer of medical equipment in the Asian continent after Japan, 
China, and South Korea [8]. The inclination of pharmacoeconomics is in 
designing affordable health-care packages for India [9].
A GLIMPSE OF THE INITIATIVES OF THE GOVERNMENT TO 
ENHANCE HEALTH SECTOR
Recent policy decisions taken by the Ministry of Health and Family 
Welfare have yielded creditable results. The outflow in health care is Rs. 
22,476 crore for the year 2013-2014 and the projected expenses for the 
year 2016-2017 are Rs. 31,300 crore. The focus is on providing standard 
health-care facilities to all sectors of the society at affordable rates.
“Kayakalp” an innovative scheme was launched in 2015 to provide 
enhanced hygiene and sanitation facilities to the public at government 
health centers. More than Rs. 140,376 crores released to the States/UTs 
as grants-in-aid till 31st March 2016, to support the State Governments 
and the Union territories to upgrade health systems.
•	 The	government	has	rolled	out	a	new	initiative	Affordable	Medicine	
and Reliable Implants for Treatment (AMRIT) that offers cancer and 
cardiac patients an equal opportunity to undergo treatment without 
spending too much. AMRIT stores started at AIIMS, New Delhi and to 
be rolled out in 14 Central Government Hospitals. These stores will 
sell 202 cancer drugs and 186 cardiovascular drugs and 148 types 
of cardiac implants.
•	 The	National	Health	Mission	 aims	 at	 strengthening	 the	health	
infrastructure by providing free drugs and diagnostics and more than 
3061 crore approved in 2015-2016 for free drugs and more than Rs. 
265	crore	provided	for	free	diagnostics.	This	would	definitely	enhance	
better health standards and reduce the OOP expenditure on health.
•	 The	biggest	National	Survey	in	the	world	for	13	tuberculosis	(TB)	
drugs launched and the procurement of 500 GeneXpert machines 
for TB detection in all the districts.
•	 The	National	Vector	Borne	Disease	Control	Program	was	launched	on	
11th February 2016 to eradicate Malaria and Kala-azar throughout the 
nation and especially in sensitive districts or states. The scheme was 
successful in eliminating 502 out of 625 endemic blocks (80%). Some 
of the states are Bihar, Jharkhand, West Bengal, and Uttar Pradesh.
•	 Initiatives	 for	National	Programme	 for	Prevention	and	Control	of	
Cancer, Diabetes, Cardiovascular Diseases and Stroke to combat 
NCDs has been established in 195 district cells, 201 district clinics, 
65 cardiac care units, 61-day care centers, and 1362 clinics.
•	 National	Dialysis	Programme	under	PPP	mode	and	a	new	health	
protection scheme for the common person on a protection cover of 




source of health care related information.
•	 Project	Kilkari	was	 launched	with	an	 interactive	voice	 response-
based mobile service to enhance awareness among pregnant women, 
parents of children on institutional delivery, antenatal care, postnatal 
care, immunization, etc., with 2 minutes long weekly session available 
in all regional languages.
•	 Streamlining	voluntary	blood	donation	by	enhancing	 safety	and	
quality through E-RaktKosh and linking all licensed blood banks in 
public and private health care.
•	 E-Hospital,	an	online	registration	system	for	outpatient	department	
appointments started in 38 hospitals and more than 2.38 lakh online 
registration-based appointments as on 26 May 2016. This initiative 
cuts travel expenses, saves man-hours, and delivers greater patient 
satisfaction.
•	 M-Cessation	for	Tobacco	is	an	IT	tool	designed	to	deter	the	use	of	
tobacco products and adopt a healthier lifestyle.
•	 Sugam	an	e-Governance	portal	for	Central	Drugs	Standard	Control	
Organization that has facilities to process import applications, drug 
Fig. 1: Causes of death in India ,Government of India, The Ministry 
of Health and Family welfare
Table 1: Health spending and governmental health spending, 
2000 and 2012










2000 2012 2000 2012 2012
India 4.3 3.8 27.0 30.5 4.3
Germany 10.4 11.3 79.5 76.7 19.3
Mexico 5.1 6.1 46.6 51.8 15.8
China 4.6 5.4 38.8 56.0 12.5
Singapore 2.7 4.2 45.0 35.9 11.1
United Kingdom 6.9 9.3 79.1 84.0 16.2
United States 13.1 17.0 43.0 47.0 20.0
Source: WHO. World Health Statistics, 2015. Accessed June 27, 2015. GDP: Gross 
domestic product
Table 2: Vital statistics on BR, DR, LE, TFR, MMR, IMR
S. No. Parameters 1951 1981 1991 2001 Current levels
1 Birth rate (per 1000 population 40.8 33.9 29.5 25.4 21.4 (2013)
2 Death rate (per 1000 population) 25.1 12.5 9.8 8.4 7.0 (2013)
3 TFR 6.0 4.5 3.6 3.1 2.3 (2013)
4 MMR (per 100,000 live births) NA NA 398 (1997-1998) 301 (2001-2003) 167 (2011-2013)
5 Infant mortality rate (per 1000 
live births)
146 (1951-1961) 110 80 66 40 (2013)
6 Life expectation at























Source: The office of the Registrar General and Census Commissioner, India. http://apps.who.int/iris/bitstream/10665/170250/1/9789240694439_eng.
pdf?ua=1&ua=1. NA: Not available, BR: Birth rate, DR: Death rate, LE: Life expectancy, TFR: Total fertility rate, MMR: Maternal mortality ratio, IMR: Infant mortality ratio
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registration, and permit to import small quantities of drugs for 
personal use.
•	 Swasth	Bharat	Mobile	App	provides	 information	on	 symptoms,	
disease	conditions,	 treatment,	public	health	alerts,	 first	 aid,	 and	
healthy lifestyle.
•	 Mission	 Indradhanush	was	 launched	on	December	25,	2014,	 to	
ensure full immunization and cover all children up to the age of 
2 years [10].
INSIGHT TO THE FUTURE
Countries such as Brazil, Korea, and Thailand had poor health-care 
systems, OOP spending was too high, low per capita income and so on. 
Combating all the challenges, these countries have made significant 
reforms in their health care and now they are successful in their 
endeavors. India’s health-care needs a tremendous change for its 
future development and can look up to the success stories of countries 
that had a turnaround in their strategies. Investments, efficiency, cost 
burden, sound policy, and public-private partnership in health care is 
the need of the hour.
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Table 3: Top 10 Pharma companies in India 2016






on 16th January, 
2016 (in crores)
1 Sun pharmaceuticals 1983 Rs. 189,139
2 Lupin 1968 Rs. 76,613
3 Dr. Reddy’s 
laboratories
1984 Rs. 50,102
4 Cipla 1935 Rs. 48,788
5 Aurobindo 1986 Rs. 47,578
6 Cadila 1951 Rs. 31,541
7 Divis Laboratories 1990 Rs. 28,609
8 GlaxoSmithKline 1924 Rs. 26,954
9 Glenmark 1977 Rs. 23,410
10 Torrent Pharma 1969 Rs. 22,392
Source: Listz.in
